[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-artery-stenosis-atherosclerotic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-artery-stenosis-atherosclerotic":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,70,99,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100503403","effects-of-percutaneous-transluminal-renal-angioplasty-of-atherosclerotic-renal-artery-stenosis-in-high-risk-patients-100503403",false,"NCT05834803","Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.","Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients - a Danish Nationwide Randomized Sham-Controlled Study.","DAN-PTRAII","Inclusion Criteria:\n\n1. One or more severe atherosclerotic renal artery stenoses defined as a stenosis ≥70% by catheter-based angiography.\n2. In addition, at least one of the following high-risk clinical syndromes:\n\n   1. Resistant hypertension with average 24-hour ambulatory systolic blood pressure ≥150 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.\n   2. Rapidly declining kidney function with a reduction in estimated GFR of \\>5 mL\u002Fmin per 1.73m2 per year and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.\n   3. Hospital admissions with acute decompensated heart failure (≥2 hospitalizations for heart failure or ≥1 hospitalizations for sudden, \"flash\" pulmonary edema) with no obvious explanations such as nonadherence, left ventricular ejection fraction \\\u003C40%, or valvular heart disease and average 24-hour ambulatory systolic blood pressure ≥140 mmHg despite ≥3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses.\n\nAll 24-hour ambulatory blood pressure monitorings are performed after nurse-administered medication.\n\nExclusion Criteria:\n\n* Unable to provide informed consent.\n* Treatment-resistant heart failure episodes presumed caused by renovascular disease.\n* Rapidly declining kidney function\u002Facute kidney failure approaching the need for dialysis presumed caused by renovascular disease.\n* Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization.\n* Pregnancy or unknown pregnancy status in female of childbearing potential.\n* Kidney size \\\u003C7 cm (pole to pole length) supplied by target vessel.\n* Previous kidney transplant.\n* Previous PTRA treatment.\n* Presence of a renal artery stenosis not amenable for treatment with a stent.\n\nPatients who are not eligible for randomization but treated with renal artery stenting outside the protocol are followed according to the DAN-PTRAII protocol in order to account for all PTRA treatments performed in Denmark in the study period.\n\nPatients treated with renal artery stenting without randomization in the study period include patients with:\n\n1. Treatment-resistant heart failure episodes presumed caused by renovascular disease.\n2. Rapidly declining kidney function\u002Facute kidney failure approaching the need for dialysis presumed caused by renovascular disease.\n3. At least one of the listed high-risk clinical syndromes AND one or more significant atherosclerotic renal artery stenoses defined as a stenosis of 50-69% by catheter-based angiography with:\n\n   * a mean translesional gradient of ≥10 mm Hg, or\n   * a systolic translesional gradient of ≥20 mm Hg, or\n   * a renal fractional flow reserve (Pd\u002FPa) of ≤0.8","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to document a beneficial effect of percutaneous transluminal renal angioplasty (PTRA) of atherosclerotic renal artery stenosis in high-risk patients selected according to the criteria used in the DAN-PTRA study. The main questions the trial aims to answer are if renal artery stenting compared with optimal medical treatment alone has beneficial effects on:\n\n* Blood pressure\n* Kidney function\n* Hospitalizations for heart failure",[27,28,29,30,31],"Renovascular Hypertension","Renovascular Hypertension With Renal Failure","Heart Failure","Renal Artery Stenosis Atherosclerotic","Percutaneous Transluminal Angioplasty","RECRUITING","2026-04-20",{"date":35,"type":36},"2026-04-23","ACTUAL",{"date":38,"type":36},"2023-06-26",{"date":40,"type":21},"2027-06-01",{"name":42,"class":43},"University of Aarhus","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100601511","a-placebo-controlled-trial-of-fractional-flow-reserve-guided-percutaneous-renal-artery-stenting-among-atherosclerosis-renal-vascular-hypertension-patients-100601511","NCT07111442","A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients","Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Versus Sham Procedure In Atherosclerosis Renal-vascular Hypertension Patients: a Double-blinded Multicenter Randomized Placebo-control Trial","FAIR","Inclusion Criteria:\n\n1. Male or female subjects aged 18 years or older.\n2. Documented history of hypertension and currently taking two or more antihypertensive medications with uncontrolled blood pressure (defined as daytime systolic BP ≥135 mmHg and\u002For diastolic BP ≥85 mmHg on optimized medication therapy, as measured by baseline ABPM).\n3. Clinical evidence suggestive of renal artery stenosis, and scheduled for renal angiography.\n4. Willing and able to provide written informed consent prior to initiation of any study-related procedures, and willing to comply with all study requirements.\n5. Renal angiography shows ≥70% to \\\u003C99% stenosis in at least one main renal artery with a reference vessel diameter of ≥4.0 mm.\n\nExclusion Criteria:\n\n1. Systolic BP ≥200 mmHg and\u002For diastolic BP ≥120 mmHg on the day of randomization.\n2. Suspected non-atherosclerotic causes of RAS, such as fibromuscular dysplasia or large-vessel vasculitis.\n3. Pregnant or breastfeeding women.\n4. Participation in another clinical trial that, in the investigator's opinion, could interfere with this study.\n5. Stroke or TIA within 3 months and known ≥70% carotid artery stenosis.\n6. Major surgery, myocardial infarction, or any interventional procedure within the past 30 days.\n7. Known LVEF \\\u003C30%.\n8. Life expectancy ≤1 year.\n9. Known allergy to contrast media or to any of the following medications: aspirin, clopidogrel.\n10. History of renal transplantation.\n11. Prior renal artery stenting or bypass surgery.\n12. Affected kidney length \\\u003C8 cm on Doppler ultrasound.\n13. Serum creatinine \\>3.0 mg\u002FdL (265.2 μmol\u002FL) at baseline visit (measured by local laboratory).\n14. Reference vessel diameter \\\u003C4 mm or \\>8 mm on angiography.",{"count":54,"type":21},200,[24],"Objective: To determine whether percutaneous renal artery stenting guided by fractional flow reserve (FFR), in addition to standard medical therapy, provides superior therapeutic efficacy compared to medical therapy alone in patients with atherosclerotic renal artery stenosis and hypertension.\n\nStudy Design: A double-blind, multicenter, prospective, randomized, placebo-controlled (sham procedure) trial.\n\nPrimary Endpoint: The percentage reduction in daytime mean systolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) from baseline to 3 months after the procedure.\n\nStudy Population: A total of 200 patients who are potential candidates for renal artery intervention will be enrolled. Participants must meet all of the following inclusion criteria to be eligible for the study.\n\nParticipant Screening and Enrollment: Once a patient is preliminarily assessed in the outpatient clinic and meets the clinical inclusion\u002Fexclusion criteria, written informed consent will be obtained, and the patient will enter a 1-week screening period. During this period, patients will perform home blood pressure monitoring using a calibrated Bluetooth-enabled device provided by the study team, which automatically uploads data. In addition, antihypertensive medications will be standardized to optimize blood pressure management.\n\nIf home BP measurements during the screening period continue to meet inclusion criteria, baseline ABPM will be conducted.\n\nFollowing standardized renal angiography, patients whose renal anatomy meets the angiographic inclusion\u002Fexclusion criteria will undergo functional assessment of the stenotic lesion using a pressure wire and measurement of renal fractional flow reserve (FFR) under dopamine-induced maximal hyperemia, in accordance with the Standard Operating Procedure (SOP).\n\nPatients who qualify will then be randomized based on FFR results using an Interactive Response Technology (IRT) system. All eligible patients will be assigned a unique subject identification number during screening, and randomization will occur on the day of angiography, ensuring allocation concealment and unbiased group assignment.\n\nStudy Intervention: Eligible participants who meet all inclusion and exclusion criteria will undergo renal angiography. On the day of angiography, a functional assessment of renal artery stenosis will be performed according to the Standard Operating Procedure (SOP) using a pressure wire under dopamine-induced maximal hyperemia to measure the Fractional Flow Reserve (FFR).\n\n* If FFR ≥ 0.80, no renal artery stenting will be performed.\n* If FFR \\\u003C 0.80, participants will be randomized in a 1:1 ratio to one of the following two intervention arms:\n\n  * Stenting Group: Renal artery stenting\n  * Control Group: Sham procedure The randomization assignment will be blinded to participants and follow-up investigators. Only designated study investigators and the operating team will be aware of the group allocation. For participants randomized to the sham procedure, the procedure will last at least 15 minutes to simulate actual intervention according to SOP guidelines. Group allocation will remain blinded until the primary endpoint is assessed at 3 months post-procedure.\n\nAll participants, regardless of group assignment, will receive guideline-directed optimized medical therapy throughout the study period.\n\nStudy Duration and Follow-up: Participants will be followed for a total of 12 months with study visits scheduled at the following time points:\n\n* 4 weeks post-procedure (telephone visit)\n* 12 weeks (clinic visit)\n* 6 months (clinic visit)\n* 12 months (clinic visit)\n\nTo minimize the impact of antihypertensive medication adjustments on statistical outcomes, it is strongly recommended that no changes be made to antihypertensive regimens during the first 3 months after enrollment unless clinically necessary, such as in cases of:\n\n* Systolic BP \\\u003C 100 mmHg, or\n* Systolic BP \\> 180 mmHg and\u002For diastolic BP \\> 100 mmHg. All changes to antihypertensive therapy (including drug type and dosage) will be documented in detail.\n\nTo ensure consistency and quality, standardized recommendations for antihypertensive drug selection and adjustment will be provided in accordance with current hypertension management guidelines.",[30,58],"Secondary Hypertension Renal Arterial","NOT_YET_RECRUITING","2025-08-01",{"date":62,"type":36},"2025-08-08",{"date":64,"type":21},"2025-08-30",{"date":66,"type":21},"2029-08-30",{"name":68,"class":43},"Peking University First Hospital",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100586296","european-multicentre-study-of-long-term-results-following-visceral-arteries-revascularization-the-e-visar-study-100586296","NCT06913530","European Multicentre Study of Long-term Results Following Visceral Arteries Revascularization: the E-VisAR Study","E-VisAR","Inclusion Criteria:\n\n* Patients presenting with atherosclerotic disease, aneurysms, or dissection;\n* Pathologies involving one or more visceral vessels (celiac, mesenteric, renal arteries, and their branches);\n* Patients receiving revascularization, both surgical and endovascular, in elective and urgent\u002Femergent settings;\n* For the retrospective cohort, patients who underwent revascularization up to 20 years from the study launch regardless of the follow-up time.\n\nExclusion Criteria:\n\n* Absence of follow-up imaging available and\u002For reported in follow-up medical reports;\n* For the retrospective cohort, a follow-up shorter than three years.",{"count":78,"type":21},500,"OBSERVATIONAL","Visceral arteries pathologies are a broad-spectrum of conditions with an extremely low incidence, estimated at 9.2% and 6.2% per 100,000 inhabitants for chronic and acute mesenteric ischemia, respectively, and 0.01-0.2% for aneurysms. The literature regarding the topic is limited in number and fragmented, having multiple vessels involved along with rare conditions caused by different aetiologies. However, these diseases are of utmost importance considering that acute presentation is common and the treatment in urgent setting is challenging and still facing high mortality rates. There are still several grey areas regarding the treatment of these pathologies. The last decades showed an increasing utilization of an endovascular approach to treat visceral vessel diseases. On one hand, the early- and mid-term superiority of endovascular revascularization vs. open surgical repair has been demonstrated considering the reduction of morbidity and mortality, and length of stay. However, publications reporting long-term (\\> five years) are still lacking.\n\nThis study is a real-word, ambispective, multi-arm, multicenter study that aims to evaluate the long-term results of visceral vessel revascularization in different diseases, districts, and approaches. Patients will be divided according to the target vessel and index disease. For each subgroup, a comparison between endovascular and open repair will be performed.\n\nThe primary outcome is to compare endovascular and open approach in terms of survival, further divided into overall and disease-related mortality, during long term follow-up (\\> 5 years). Moreover, early and mid-term data should be considered to provide reliable results. This outcome will be stratified as well within each disease- specific arm.\n\nAt the study launch, data collection of patients who have undergone visceral vessels revascularization in the previous 20 years will begin. At the same time, all new cases of visceral vessel revascularization will be proposed for enrollment and follow-up in the prospective arm. The retrospective cohort will provide informative results regarding the long-term survival of these patients. This information will be used to adjust the sample size for the prospective cohort.",[82,83,84,85,30,86,87,88,89],"Visceral Artery Aneurysm","Mesenteric Artery Ischemia","Renal Artery Aneurysm","Renal Artery Stenosis","Renal Artery Fibromuscular Dysplasia","Chronic Mesenteric Ischemia","Visceral Artery Dissection","Mesenteric Artery Dissection","2025-03-30",{"date":92,"type":36},"2025-04-06",{"date":94,"type":21},"2025-04-01",{"date":96,"type":21},"2030-06-01",{"name":98,"class":43},"Azienda Ospedaliero-Universitaria di Modena",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":51,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":69},"100550489","fractional-flow-reserve-guided-stenting-versus-medical-therapy-in-atherosclerosis-renal-artery-stenosis-100550489","NCT06447740","Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis","Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Plus Optimal Medical Therapy Versus Optimal Medical Therapy Alone In Atherosclerosis Renal-vascular Hypertension Patients: a Multicenter Randomized Trial","Inclusion Criteria:\n\n* With recorded hypertension, AND the blood pressure is not controlled (daytime mean SBP ≥135 mmHg and\u002For DBP ≥85 mmHg based on ABPM) on 2 or more classes of anti-hypertensive drugs;\n* Evidence of renal artery stenosis and undergoing renal artery angiography;\n* Able to follow the study protocol and provide informed consent;\n* Renal artery angiography shows at least 1 main artery with stenosis of 50%-90%, AND the diameter is ≥ 4.0mm.\n\nExclusion Criteria:\n\n* SBP ≥200mmHg and\u002For DBP ≥120mmHg at the day or randomization;\n* Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis;\n* Pregnancy or unknown pregnancy status in female of childbearing potential;\n* Participation in any drug or device trial during the study period;\n* Any stroke\u002FTIA, OR with ≥70% stenosis of carotid artery;\n* Any major surgery, myocardial infarction or interventional therapy 30 days prior to study entry;\n* LVEF \\\u003C30%;\n* Comorbidity condition causing life expectancy ≤1 year;\n* Allergy to contrast or any of the following: aspirin, clopidogrel;\n* Previous kidney transplant;\n* Previous renal artery bypass surgery or stent intervention;\n* Kidney size less than 8 cm measured by ultrasound;\n* Local lab serum Cr \\>3.0 mg\u002Fdl (265.2μmol\u002Fl) on the day of randomization;\n* Reference vessel size \\\u003C4 mm or \\>8 mm.",{"count":54,"type":21},[24],"Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. Based on the primary finding of FAIR-pilot study (NCT05732077), FFR-guided renal artery stenting is practical.\n\nThe overall purpose of the FAIR trial is to compare the clinical outcomes and safety of FFR-guided stenting plus optimal medical treatment (OMT) versus OMT alone in patients with renal-vascular hypertensive patients.\n\nWith the 'all comers' design, participants met the inclusive\u002Fexclusive criteria will be enrolled, and hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, patients will be treated with OMT alone and follow up. If FFR is \\\u003C0.80, participants will be randomized to stenting in the renal artery plus OMT or OMT alone on a 1:1 ratio. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.",[30,58],"2024-08-13",{"date":112,"type":36},"2024-08-16",{"date":114,"type":36},"2024-06-03",{"date":116,"type":21},"2027-04-03",{"name":68,"class":43},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},"100495506","fractional-flow-reserve-to-determine-atherosclerosis-renovascular-hypertension-stenting-100495506","NCT05732077","Fractional Flow Reserve to Determine Atherosclerosis Renovascular Hypertension Stenting","Fractional Flow Reserve to Determine the ApproprIateness of Percutaneous Renal Artery Intervention in Atherosclerosis Renovascular Hypertension Patients: a Pilot Randomized Trial","FAIR-Pilot","Inclusion Criteria:\n\n* With recorded hypertension, AND the blood pressure is not controlled (SBP ≥140mmHg and\u002For DBP ≥90mmHg) on 2 or more classes of anti-hypertensive drugs;\n* Evidence of renal artery stenosis and undergoing renal artery angiography;\n* Able to follow the study protocol and provide informed consent;\n* Renal artery angiography shows at least 1 main artery with stenosis of 50%-90%, AND the diameter is ≥ 4.0mm.\n\nExclusion Criteria:\n\n* SBP ≥200mmHg and\u002For DBP ≥120mmHg at the day or randomization;\n* Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis;\n* Pregnancy or unknow pregnancy status in female of childbearing potential;\n* Participation in any drug or device trial during the study period;\n* Any stroke\u002FTIA, OR with ≥70% stenosis of carotid artery;\n* Any major surgery, myocardial infarction or interventional therapy 30 days prior to study entry;\n* LVEF \\\u003C30%;\n* Comorbid condition causing life expectancy ≤1 year;\n* Allergy to contrast or any of the following: aspirin, clopidogrel;\n* Previous kidney transplant;\n* Previous renal artery bypass surgery or stent intervention;\n* Kidney size less than 8 cm measured by ultrasound;\n* Local lab serum Cr \\>3.0 mg\u002Fdl (265.2μmol\u002Fl) on the day of randomization;\n* Reference vessel size \\\u003C4 mm or \\>8 mm.",{"count":127,"type":21},100,[24],"Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. The goal of this clinical trial is to learn whether Fraction Flow Reserve (FFR) is appropriate to determine stenting in hypertension patients with atherosclerosis renal artery stenosis. The main questions it aims to answer are:\n\n* Is it appropriate to use FFR to determine whether or not stenting for hypertension patients with atherosclerosis renal artery stenosis?\n* To provide detailed data supporting design of further trial, such as sample size calculating, cut-off value for FFR in renal artery stenosis, etc.\n\nParticipants met the inclusive\u002Fexclusive criteria will be randomized to stenting or not in the renal artery, then hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, randomization will be applied. If FFR is \\\u003C0.80, randomization will be ignored, and stenting will be performed as planned. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.",[30,58],"2024-06-04",{"date":133,"type":36},"2024-06-06",{"date":135,"type":36},"2023-01-31",{"date":137,"type":21},"2025-03-31",{"name":68,"class":43},13]